Reta vs Wegovy: What the Trial Data Shows

Weight Loss — 2026-05-08

Wegovy is the obesity-indicated brand of sema — same molecule as Ozempic, just dosed up to 2.4 mg weekly instead of 1–2 mg. That higher dose puts Wegovy in direct comparison with reta on the metric most weight-loss research cares about: total body weight reduction. This article walks through how the two compare on the data, the mechanism, the side effects, and the practical research design implications.

Researcher special: code WELCOME at checkout unlocks 35% off reta 10mg, reta 20mg, sema 10mg, and the Metabolic Stack. Every vial ships with a batch-matched COA.

Wegovy and Reta: One-Line Summaries

• Wegovy = sema (GP-1 mono-agonist) at the obesity-labeled 2.4 mg weekly dose
• Reta = triple agonist (GP-1 + GIP + glucagon) at up to 12 mg weekly in the Phase 2 trial

If you've already read our reta vs Ozempic comparison, the molecule on the sema side is identical — what changes between Ozempic and Wegovy is dose, label, and the trial program that supports each indication. The comparison to reta is more direct here because both compounds are being studied at their *obesity* doses.

Head-to-Head: Weight Loss

This is the comparison researchers actually want:

A few things stand out:

1. Reta's lowest tested dose (4 mg) roughly matches Wegovy's top dose (2.4 mg) for weight loss — both around 17%. So the *floor* of reta is roughly the *ceiling* of Wegovy.
2. Reta's top dose nearly doubles Wegovy — 24% vs. 15%.
3. Reta reaches its top effect in less time — 48 weeks vs. 68.

The magnitude differential is the headline finding. There is no sema dose that has been studied that produces reta-12mg-tier effects. The receptor coverage simply isn't sufficient.

Why the Gap Exists: Mechanism

Wegovy and reta are both injectable, both weekly, both act on GP-1. Where they diverge:

The glucagon-receptor arm is the structural novelty. GP-1 alone reduces *intake* — appetite suppression and delayed gastric emptying drive a caloric deficit. Glucagon receptor activation increases *output* — resting energy expenditure goes up, hepatic fat is preferentially oxidized, thermogenesis modestly increases.

Wegovy works on one side of the equation. Reta works on both.

The GIP arm is the third piece. GIP was historically considered metabolically inert or even counterproductive, but the success of triz (a GP-1/GIP dual agonist) reframed that view. GIP appears to enhance insulin sensitivity and offer partial GI tolerability buffering — it lets researchers titrate reta to higher effective GP-1 exposure than would be tolerable with GP-1 alone.

Dosing and Titration

Reta's titration spans a wider absolute range (2 → 12 mg vs. 0.25 → 2.4 mg) but uses the same 4-weekly step cadence. Skipping titration steps with either compound dramatically increases GI dropout — the published trial schedules are not optional features.

For researchers new to reta, our reta beginner dosing protocol walks through a gentler 20/30/40 unit ramp into the 2 mg starting dose. The full Phase 2 schedule is in our reta dosing guide.

Side Effects: The Same Class, Bigger Magnitude

Both Wegovy and reta produce class-typical GP-1 side effects:

• Nausea, vomiting, diarrhea (dose- and titration-dependent)
• Constipation in some subjects
• Class-monitored: pancreatitis, gallbladder events, retinopathy

Reta adds:

• Mild heart rate elevation (3–7 bpm) — glucagon-mediated
• Transient transaminase elevations
• Higher overall GI burden, especially during the 8 → 12 mg escalation

In the Phase 2 obesity trial, the discontinuation rate due to adverse events was ~6% in the 4 mg arm and ~16% in the 12 mg arm. Wegovy's STEP 1 trial showed ~7% discontinuation due to GI adverse events. The difference is concentrated at reta's top dose — at reta's lower doses, tolerability is comparable to Wegovy.

This is one reason many research protocols target the 8 mg reta dose rather than 12 mg. The endpoint is ~22.8% vs. 24.2% — nearly the same — at substantially better tolerability.

Lean Mass: Often Missed

Both compounds drive body weight loss without specific lean-tissue protection. Roughly 25–30% of weight lost on either compound is lean mass — a known issue with the GP-class.

This is why most modern recomp protocols pair reta (or any GP-class compound) with a GH-axis peptide like tesamorelin, which preferentially redistributes fat from visceral compartments and supports lean mass via IGF-1 elevation. See reta vs tesamorelin and the Shred Stack for the rationale.

A research protocol targeting *body composition* rather than *body weight* should not run reta or Wegovy in isolation if the design can support a stack.

When Wegovy Wins

There are research questions where Wegovy is the better choice:

• Established safety baseline: Sema has years of post-approval safety data; reta is Phase 2.
• Smaller effect size needed for design: If a study is powered for moderate weight loss, the larger reta effect can saturate the endpoint.
• Tolerability ceiling matters: Subjects who failed prior GP-1 escalation may not be candidates for the more aggressive reta protocol.
• Cost-per-unit-effect at lower doses: At the 4 mg reta dose vs. 2.4 mg Wegovy dose, the magnitude is similar but availability differs.

When Reta Wins

• Maximum weight loss endpoint: No sema dose matches reta's top-end effect.
• Glucagon-receptor research: Wegovy doesn't touch this axis.
• Energy expenditure as primary: Glucagon arm directly addresses this.
• Newer-generation comparator studies: Reta is the relevant benchmark for next-gen compounds.

Sourcing for Comparator Studies

If your design is a head-to-head reta vs. Wegovy-dose-sema comparison, batch-matched material across both compounds is essential. Variable potency confounds dose-response data, and sourcing from a single supplier with batch-COAs eliminates that variable.

Use code WELCOME at checkout for 35% off reta 10mg, reta 20mg, sema 10mg vials, and the Metabolic Stack. Every vial includes a batch-matched COA showing 99%+ HPLC purity, ships from a US facility, and uses bacteriostatic-water-compatible reconstitution.

Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.